SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sai Life Sciences reports 57% rise in Q4 consolidated net profit

14 May 2025 Evaluate

Sai Life Sciences has reported results for fourth quarter (Q4) and year ended March 31, 2025.

The company has reported 46.24% rise in its net profit at Rs 89.94 crore for the quarter under review as compared to Rs 61.50 crore for the same quarter in the previous year. The total income of the company increased by 33.61% at Rs 576.83 crore for Q4FY25 as compared Rs 431.73 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 57.26% rise in its net profit at Rs 88.27 crore for fourth quarter ended March 31, 2025 as compared to Rs 56.13 crore for the same quarter in the previous year. The total income of the company increased by 33.12% at Rs 589.11 crore for Q4FY25 as compared Rs 442.55 crore for the corresponding quarter previous year.

For the year ended March 31, 2025, the company has reported 82.15% rise in its net profit at Rs 173.46 crore as compared to Rs 95.23 crore for the previous year. The total income of the company increased by 15.98% at Rs 1,679.38 crore for year under review as compared to Rs 1,448.01 crore for year ended March 31, 2024.

For the year ended March 31, 2025, on the consolidated basis, the company has reported over two folds jump in its net profit at Rs 170.13 crore as compared to Rs 82.81 crore for the previous year. The total income of the company increased by 15.87% at Rs 1,731.35 crore for year under review as compared to Rs 1,494.27 crore for year ended March 31, 2024.

Sai Life Sciences Share Price

970.50 -1.35 (-0.14%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×